Prostate Health Index - Improving screening in men with family history

Nature Reviews Urology

Volumn 10, Issue 9, 2013, Pages 497-498

  Loeb, Stacy ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; ERECTILE DYSFUNCTION; FAMILY HISTORY; FOOD AND DRUG ADMINISTRATION; HUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE VOLUME; VALIDATION PROCESS; BLOOD; MALE; NOTE; PROSTATE TUMOR; PROSTATIC NEOPLASMS;

HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84883740350     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2013.169     Document Type: Article

References (10)

1. American Urological Association. Early Detection of Prostate Cancer: American Urological Association Guideline. Detection of Prostate Cancer [online], http://www.auanet.org/education/guidelines/prostate-cancer-detection. cfm (2013).
2. Catalona, W. J. et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J. Urol. 185, 1650-1655 (2011).
3. Le, B. V. et al. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J. Urol. 183, 1355-1359 (2010).
4. Guazzoni, G. et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: Results of a prospective study in a clinical setting. Eur. Urol. 60, 214-222 (2011).
5. Scattoni, V. et al. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. J. Urol. 190, 496-501 (2013).
6. Lazzeri, M. et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: A multicentric European study. Eur. Urol. 63, 986-994 (2013).
7. Lazzeri, M. et al. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: Results from a multicentre European study, the PROMEtheuS project. BJU Int. 112, 313-321 (2013).
8. Schroder, F. H. et al. Prostate-cancer mortality at 11 years of follow-up. N. Engl. J. Med. 366, 981-990 (2012).
9. Loeb, S., Carter, H. B., Berndt, S. I., Ricker, W. & Schaeffer, E. M. Complications after prostate biopsy: Data from SEER-Medicare. J. Urol. 186, 1830-1834 (2011).
10. Lughezzani, G. et al. Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy. J. Urol. 188, 1144-1150 (2012).